New Technology for Chronic Pain

There is another groundbreaking invention forcing its way to the market. There may be new hope for those patients who typically have not responded to any treatment protocol performed in accordance with Multidrug Therapy (MDT), or surface electro-stimulation. A new pain relief therapy has been discovered and is proven by clinical studies as effective and has been cleared by the DFA. The new device that is used is a non-invasive, non-narcotic method for treatment of severe, chronic, high-intensity oncologic and neuropathic pain, which is resistant to morphine and other drugs.

 This therapy does not use a biochemical but rather the biophysical process. With continuous therapy, pain gradually lessens and eventually disappears in a high percentage of cases. The device utilizes the electrical impulses instead of narcotic painkillers. These are intended for patients who suffer chronic pain, especially to those who do not respond to narcotic painkillers.

 Commonly, these people suffer consistent pain and are not responsive even to high doses and powerful narcotic drugs. Chronic pain therapy is a multi-billion dollar industry with anticipated thousands of patients frustrated to unleash themselves from ineffective drugs and their accompanying side effects.

 The sad part is that the business seems to be a failure since the start of its sales in February last year. But a few days ago, improvements have started to take place. Investors who were disappointed with the last year of sales have now been given a light of hope.

 In the present, there are lots of studies that are conducted to test the effectiveness of the said therapy. They are expected to present their patient case studies that will either approve or disprove the effectiveness of their non-narcotic approach to treat severe pain from cancer, chemotherapy-induced peripheral neuropathy (CIPN), failed back surgery, phantom limb syndrome, pain from shingles and other kinds of chronic pain. A success in the clinical study about the effectiveness of the therapy to treat Chemotherapy-induced peripheral neuropathy may warrant a peer-reviewed article that will be published in a medical journal. This will surely bring the product to its rise.

 Today, the product is not sold to the United States but In Virginia, there is a study conducted to assess the effectiveness of the said technology. If the studies will support what is claimed, the sales may be increased and consequently, more investors may be attracted and an increased supply may surely follow.